Other PET tracers for neuroendocrine tumors

PET Clinics

Volumn 9, Issue 1, 2014, Pages 57-62

  Koopmans, Klaas Pieter ^a   Glaudemans, Andor W J M ^b  

^a MARTINI HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Neuroendocrine tumor; Pancreatic islet cell tumor

Indexed keywords

5 HYDROXYTRYPTOPHAN C 11; CARBIDOPA; CATECHOLAMINE; METAIODOBENZYLGUANIDINE I 124; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2; (3 IODOBENZYL)GUANIDINE; 5 HYDROXYTRYPTOPHAN; CARBON;

ARTICLE; DECARBOXYLATION; HUMAN; IMAGE QUALITY; METASTASIS; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PANCREAS CARCINOMA; PANCREAS ISLET CELL TUMOR; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; INTESTINE TUMOR; PANCREAS TUMOR; PROCEDURES; SCINTISCANNING; STOMACH TUMOR;

3-IODOBENZYLGUANIDINE; 5-HYDROXYTRYPTOPHAN; CARBON RADIOISOTOPES; HUMANS; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS;

EID: 84888343678     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2013.08.009     Document Type: Review

References (23)

1. S. Adams, R. Baum, and T. Rink Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur J Nucl Med 25 1 1998 79 83
2. T. Belhocine, J. Foidart, and P. Rigo Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67 Nucl Med Commun 23 8 2002 727 734
3. C. Pasquali, D. Rubello, and C. Sperti Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22 6 1998 588 592
4. E. Garin, F. Le Jeune, and A. Devillers Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors J Nucl Med 50 6 2009 858 864
5. H.B. Fiebrich, A.H. Brouwers, and K.P. Koopmans Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients Eur J Cancer 45 13 2009 2312 2315
6. P.L. Jager, R. Chirakal, and C.J. Marriott 6-L-18F- fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications J Nucl Med 49 4 2008 573 586
7. L. Kolby, P. Bernhardt, and A.M. Levin-Jakobsen Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters Br J Cancer 89 7 2003 1383 1388
8. A. Altmann, M. Kissel, and S. Zitzmann Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma J Nucl Med 44 6 2003 973 980
9. N. Furuta, H. Kiyota, and F. Yoshigoe Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy Int J Urol 6 3 1999 119 124
10. V. Hartung-Knemeyer, S. Rosenbaum-Krumme, and C. Buchbender Malignant pheochromocytoma imaging with [124I]mIBG PET/MR J Clin Endocrinol Metab 97 11 2012 3833 3834
11. M. Charron Contemporary approach to diagnosis and treatment of neuroblastoma Q J Nucl Med Mol Imaging 57 1 2013 40 52
12. Y. Seo, W.C. Gustafson, and S.F. Dannoon Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model Mol Imaging Biol 14 6 2012 735 742
13. C.L. Lee, H. Wahnishe, and G.A. Sayre Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET Med Phys 37 9 2010 4861 4867
14. K.P. Koopmans, O.N. Neels, and I.P. Kema Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results Crit Rev Oncol Hematol 71 3 2009 199 213
15. P. Bjurling, Y. Watanabe, and M. Tokushige Syntheses of β-11C-labelled L-tryptophan and 5-hydroxy-L-tryptophan using a multi-enzymatic reaction route J Chem Soc Perkin 1 1 7 1989 1331 1334
16. O.C. Neels, P.L. Jager, and K.P. Koopmans Development of a reliable remote-controlled synthesis of β-[11C]-5-hydroxy-L-tryptophan on a Zymark robotic system J Labelled Comp Rad 49 2006 889 895
17. K.P. Koopmans, O.C. Neels, and I.P. Kema Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography J Clin Oncol 26 9 2008 1489 1495
18. B. Eriksson, M. Bergstrom, and A. Lilja Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors Acta Oncol 32 2 1993 189 196
19. H. Orlefors, A. Sundin, and L. Lu Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5- hydroxytryptophan positron emission tomography Eur J Nucl Med Mol Imaging 33 1 2006 60 65
20. H. Orlefors, A. Sundin, and H. Ahlstrom Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors J Clin Oncol 16 7 1998 2534 2541
21. H. Orlefors, A. Sundin, and U. Garske Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography J Clin Endocrinol Metab 90 6 2005 3392 3400
22. R. Boellaard, M.J. O'Doherty, and W.A. Weber FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Eur J Nucl Med Mol Imaging 37 1 2010 181 200
23. E. Bombardieri, F. Giammarile, and C. Aktolun 131I/123I- metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging Eur J Nucl Med Mol Imaging 37 12 2010 2436 2446